+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2012-06-18Number of Pages: 78

Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts 2010 - 2017

CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION

1.2 SCOPE OF THE REPORT

1.3 METHODOLOGY

 

CHAPTER 2 EXECUTIVE SUMMARY

 

CHAPTER 3 ASTHMA AND COPD MARKET

3.1 MARKET OVERVIEW

3.2 INCREASING ASTHMA AND COPD PREVALENCE AND TRENDS

      3.2.1 Region wise estimate of asthma patients, 2007-2011(Million) 

      3.2.1 Region wise Estimate of COPD patients, 2007-2011 (Million) 

3.3 PRODUCT TREND ANALYSIS

3.4 ASTHMA DISEASE OVERVIEW

      3.4.1 ASTHMA PATIENT FORECASTS BY GEOGRAPHY, 2012 - 2017 (MILLION) 

      3.4.2 PATIENTS SUFFERING FROM ASTHMA, CHINA, 2012 - 2017 (MILLION) 

3.5 COPD DISEASE OVERVIEW

3.6 PATIENT FORECASTS – COPD PATIENTS BY GEOGRAPHY,  2012 – 2017 (MILLION) 

      3.6.1 PATIENTS SUFFERING FROM COPD, CHINA, 2010 - 2017 (MILLION) 

3.7 GROWTH DRIVERS

      3.7.1 INCREASE IN POPULATION SUSCEPTIBLE TO INDOOR AIR POLLUTANTS

      3.7.2 DAILY EXPOSURE TO HAZARDOUS WORKING ENVIRONMENT LEADS TO GROWTH OF ASTHMA AND COPD

      3.7.3 GROWING AGING POPULATION

      3.7.4 INCREASING POPULATION OF SMOKERS WILL SUPPORT THE GROWTH OF ASTHMA AND COPD MARKET

      3.7.5 INFLUX OF POLLUTANTS IN THE AIR

      3.7.6 INCREASE IN DISPOSABLE INCOME AND HEALTHCARE FACILITY

3.8 MARKET RESTRAINTS

      3.8.1 PATENT EXPIRY OF MANY BLOCKBUSTER BRANDS WILL CREATE PRESSURE

      3.8.2 OVERALL HIGH COST OF ASTHMA TREATMENT IS A CHALLENGE FOR PATIENTS

              3.8.2.1 Uninsured people - a challenge

      3.8.3 LONG TREATMENT CONTINUATION

3.9 PORTER FIVE FORCES MODEL

      3.9.1 BARGAINING POWER OF SUPPLIER

      3.9.2 BARGAINING POWER OF BUYER

      3.9.3 RIVALRY AMONG EXISTING COMPETITORS

      3.9.4 THREAT OF NEW ENTRANTS

      3.9.5 THREAT OF SUBSTITUTE PRODUCTS OR SERVICES

 

CHAPTER 4 ASTHMA AND COPD MARKET BY PRODUCT TYPE

4.1 ASTHMA AND COPD DRUG REVENUE FORECASTS

4.2 BRONCHODILATORS

      4.2.1 REVENUE FORECASTS FOR BRONCHODILATORS

      4.2.2 SHORT ACTING BRONCHODILATORS

                4.2.2.1 Revenue Forecasts for Short-Acting Bronchodilators

      4.2.3 LONG-ACTING BRONCHODILATORS

                4.2.3.1 Revenue Forecasts for Long-Acting Bronchodilators

      4.2.4 ANTICHOLINERGICS BRONCHODILATORS

                4.2.4.1 Revenue Forecasts Anticholinergics

4.3 ANTI-INFLAMMATORIES

                4.3.1.1 Revenue Forecasts for Anti-Inflammatories

      4.3.2 INHALED CORTICOSTEROIDS

                4.3.2.1 Revenue Forecasts for Inhaled Corticosteroids

      4.3.3 ANTI-LEUKOTRIENES

                4.3.3.1 Revenue Forecasts for Anti-Leukotrienes

      4.3.4 MONOCLONAL ANTIBODIES

                4.3.4.1 Revenue Forecasts for Monoclonal Antibodies

4.4 COMBINATION THERAPIES

      4.4.1 REVENUE FORECASTS FOR COMBINATION THERAPIES

 

CHAPTER 5 ASTHMA DRUG MARKET ANALYSIS

5.1 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION) 

5.2 ASTHMA PATHOPHYSIOLOGY

5.3 ASTHMA DRUG REVENUE BY BRNAD, 2009 - 2011 (USD MILLION) 

      5.3.1 MEDICATION

               5.3.1.1 Short-Acting Beta2-Agonists

               5.3.1.2 Inhaled Corticosteroids

               5.3.1.3 Long-Acting Bronchodilators

               5.3.1.4 Leukotriene Modifiers

               5.3.1.5 Mast Cell Stabilizers

               5.3.1.6 Methyxanthines

               5.3.1.7 Monoclonal Antibodies

               5.3.1.8 Oral Corticosteroids

5.4 ADHERENCE

      5.4.1 MEDICATION ADHERENCE BY AGE GROUP, 2011

5.5 ASTHMA - COST TRENDS

5.6 EMERGING TREATMENT OPTIONS FOR ASTHMA

 

CHAPTER 6 COPD MARKET ANALYSIS

6.1 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION) 

6.2 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION) 

6.3 EXISTING MEDICATION FOR COPD

6.4 COPD DRUG MARKET SHARE 2011 VS 2017

      6.4.1 BRONCHODILATORS

      6.4.2 LONG-ACTING ANTICHOLINERGICS

      6.4.3 LONG-ACTING Β2-AGONISTS

      6.4.4 SHORT-ACTING BRONCHODILATORS

6.5 INHALED CORTICOSTEROIDS

6.6 COMBINATION THERAPIES

      6.6.1 Β2-AGONISTS AND ANTICHOLINERGICS

      6.6.2 LABAS AND INHALED CORTICOSTEROIDS

6.7 EMERGING TRENDS IN COPD THERAPY

 

CHAPTER 7 DRUG BRAND DYNAMICS

7.1 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014

7.2 SYMBICORT REVENUE (USD MILLION), 2009 – 2014

7.3 SPIRIVA REVENUE (USD MILLION), 2009 - 2014

7.4 SINGULAIR REVENUE (USD MILLION), 2009 - 2014

 

CHAPTER 8 COMPETITIVE LANDSCAPE

8.1 COMPETITIVE STRATEGY BY KEY PLAYERS

8.2 MARKET SHARE BY KEY PLAYERS, 2011

8.3 KEY ASTHMA & COPD DRUGS BY REVENUE, 2009 – 2011 (USD MILLION)

 

CHAPTER 9 COMPANY PROFILE

9.1 NOVARTIS AG

       9.1.1 COMPANY OVERVIEW

       9.1.2 FINANCIAL OVERVIEW: 

       9.1.3 RESPIRATORY DIVISION NET SALES

       9.1.4 SEGMENT OVERVIEW

       9.1.5 GEOGRAPHICAL OVERVIEW

       9.1.6 RECENT DEVELOPMENT

9.2 MERCK & CO. 

       9.2.1 COMPANY OVERVIEW

       9.2.2 FINANCIAL OVERVIEW: 

       9.2.3 GEOGRAPHICAL OVERVIEW

       9.2.4 RECENT DEVELOPMENT

9.3 GLAXOSMITHKLINE PLC

       9.3.1 COMPANY OVERVIEW

       9.3.2 FINANCIAL OVERVIEW: 

       9.3.3 SEGMENT OVERVIEW

       9.3.4 GEOGRAPHICAL OVERVIEW

       9.3.5 RECENT DEVELOPMENT

9.4 BOEHRINGER INGELHEIM GMBH (BOEHRINGER) 

       9.4.1 COMPANY OVERVIEW

       9.4.2 FINANCIAL OVERVIEW: 

       9.4.3 SEGMENT OVERVIEW

       9.4.4 GEOGRAPHICAL OVERVIEW

       9.4.5 RECENT DEVELOPMENT

9.5 NYCOMED

       9.5.1 COMPANY OVERVIEW

       9.5.2 FINANCIAL OVERVIEW: 

       9.5.3 GEOGRAPHICAL OVERVIEW

       9.5.4 RECENT DEVELOPMENT

LIST OF FIGURES

 

FIG. 1 REGION WISE ESTIMATE OF ASTHMA PATIENTS, 2007-2011 (MILLION)

FIG. 2 REGION WISE ESTIMATE OF COPD PATIENTS, 2007-2011 (MILLION)

FIG. 3 CHINESE ASTHMA PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)

FIG. 4 CHINESE COPD PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)

FIG. 5 AIR POLLUTION MARKET SHARE FROM DIFFERENT INDUSTRIES

FIG. 6 CHILDREN AGED (0-18) UNINSURED PERCENTAGE, 2003 - 2010

FIG. 7 ASTHMA AND COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 8 BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 9 SHORT-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 10 LONG-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 11 ANTICHOLINERGICS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 12 ANTI-INFLAMMATORIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 13 INHALED CORTICOSTEROIDS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 14 ANTI-LEUKOTRIENES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 15 MONOCLONAL ANTIBODIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 16 COMBINATION THERAPIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 17 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 18 ASTHMA DRUG REVENUE BY BRNAD, 2009- 2011 (USD MILLION)

FIG. 19 MEDICATION ADHERENCE BY AGE GROUP, 2011

FIG. 20 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)

FIG. 21 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)

FIG. 22 COPD DRUG MARKET SHARE 2011 VS 2017

FIG. 23 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014

FIG. 24 SYMBICORT REVENUE (USD MILLION), 2009 - 2014

FIG. 25 SPIRIVA REVENUE (USD MILLION), 2009 - 2014

FIG. 26 SINGULAIR REVENUE (USD MILLION), 2009 - 2014

FIG. 27 PULMICORT REVENUE (USD MILLION), 2009 - 2014

FIG. 28 MARKET SHARE BY KEY PLAYERS, 2011

FIG. 29 NOVARTIS AG, PERFORMANCE CHART (2007-2011)

FIG. 30 NOVARTIS AG, MARKET SHARE BY SEGMENT IN 2011

FIG. 31 NOVARTIS AG, MARKET SHARE BY GEOGRAPHY IN 2011

FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011)

FIG. 33 MERCK & CO. MARKET SHARE BY GEOGRAPHY IN 2011

FIG. 34 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010)

FIG. 35 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2010

FIG. 36 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY GEOGRAPHY IN 2011

FIG. 37 BOEHRINGER INGELHEIM, MARKET SHARE BY SEGMENT IN 2011

FIG. 38 BOEHRINGER INGELHEIM, MARKET SHARE BY GEOGRAPHY IN 2011

FIG. 39 NYCOMED, MARKET SHARE BY GEOGRAPHY IN 2010


 
 
Back To Top